Lexicon Pharmaceuticals (LXRX) Hits New 1-Year Low at $7.40

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reached a new 52-week low during trading on Monday . The stock traded as low as $7.40 and last traded at $7.46, with a volume of 16121 shares. The stock had previously closed at $7.48.

Several equities research analysts have commented on LXRX shares. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 3rd. BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, October 4th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. Citigroup dropped their target price on Lexicon Pharmaceuticals from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, November 2nd. Finally, Gabelli reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.25.

The firm has a market cap of $792.32 million, a PE ratio of -5.91 and a beta of 0.73. The company has a quick ratio of 2.83, a current ratio of 2.90 and a debt-to-equity ratio of 8.85.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. The firm had revenue of $6.90 million for the quarter, compared to the consensus estimate of $12.56 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 168.23%. The company’s quarterly revenue was down 74.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.29) earnings per share. As a group, equities analysts predict that Lexicon Pharmaceuticals, Inc. will post -1.29 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Tocqueville Asset Management L.P. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at $164,000. Dynamic Technology Lab Private Ltd purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at $205,000. LPL Financial LLC increased its position in Lexicon Pharmaceuticals by 34.1% during the first quarter. LPL Financial LLC now owns 29,172 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 7,426 shares during the last quarter. MetLife Investment Advisors LLC increased its position in Lexicon Pharmaceuticals by 49.8% during the third quarter. MetLife Investment Advisors LLC now owns 35,705 shares of the biopharmaceutical company’s stock valued at $381,000 after acquiring an additional 11,862 shares during the last quarter. Finally, Tekla Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals during the third quarter valued at $747,000.

ILLEGAL ACTIVITY WARNING: “Lexicon Pharmaceuticals (LXRX) Hits New 1-Year Low at $7.40” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://transcriptdaily.com/2018/11/27/lexicon-pharmaceuticals-lxrx-hits-new-1-year-low-at-7-40.html.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: Cost of Equity

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply